313662-92-9

Usage

Uses

Used in Pharmaceutical Industry:
5-(2-fluorophenyl)-4H-1,2,4-triazol-3-amine is used as a potential drug candidate for its antimicrobial, antifungal, and antitumor properties. The presence of the fluorophenyl group in its structure may allow for specific interactions with biological targets, which could be beneficial for drug discovery and development.
Used in Agrochemical Industry:
In the agrochemical industry, 5-(2-fluorophenyl)-4H-1,2,4-triazol-3-amine is used as a potential active ingredient for developing new pesticides or fungicides. Its antimicrobial and antifungal properties could be harnessed to protect crops from various pathogens, thereby increasing agricultural productivity.
Understanding the chemical properties and potential uses of 5-(2-fluorophenyl)-4H-1,2,4-triazol-3-amine could lead to further research and development in both pharmaceutical and agrochemical fields, potentially resulting in the creation of new drugs or agrochemical products with improved efficacy and selectivity.

InChI:InChI=1/C8H7FN4/c9-6-4-2-1-3-5(6)7-11-8(10)13-12-7/h1-4H,(H3,10,11,12,13)

Upstream product

• 394-35-4 methyl 2-fluorobenzoate 
• 446-24-2 2-fluorobezohydrazide 

Relevant academic research and scientific papers

Design, synthesis and pharmacological evaluation of tricyclic derivatives as selective RXFP4 agonists

Relaxin family peptide receptors (RXFPs) are the potential therapeutic targets for neurological, cardiovascular, and metabolic indications. Among them, RXFP3 and RXFP4 (formerly known as GPR100 or GPCR142) are homologous class A G protein-coupled receptors with short N-terminal domain. Ligands of RXFP3 or RXFP4 are only limited to endogenous peptides and their analogues, and no natural product or synthetic agonists have been reported to date except for a scaffold of indole-containing derivatives as dual agonists of RXFP3 and RXFP4. In this study, a new scaffold of tricyclic derivatives represented by compound 7a was disclosed as a selective RXFP4 agonist after a high-throughput screening campaign against a diverse library of 52,000 synthetic and natural compounds. Two rounds of structural modification around this scaffold were performed focusing on three parts: 2-chlorophenyl group, 4-hydroxylphenyl group and its skeleton including cyclohexane-1,3-dione and 1,2,4-triazole group. Compound 14b with a new skeleton of 7,9-dihydro-4H-thiopyrano[3,4-d][1,2,4]triazolo[1,5-a]pyrimidin-8(5H)-one was thus obtained. The enantiomers of 7a and 14b were also resolved with their 9-(S)-conformer favoring RXFP4 agonism. Compared with 7a, compound 9-(S)-14b exhibited 2.3-fold higher efficacy and better selectivity for RXFP4 (selective ratio of RXFP4 vs. RXFP3 for 9-(S)-14b and 7a were 26.9 and 13.9, respectively).